Cargando…

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses

BACKGROUND: This manuscript evaluates whether specific symptoms, a symptom index (SI), CA125 and HE4 can help identify women with malignant tumors in the group of women with adnexal masses previously diagnosed with ultrasound. METHODS: This was a cross-sectional study with data collection between Ja...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pitta, Denise da Rocha, Sarian, Luis Otávio, Barreta, Amilcar, Campos, Elisabete Aparecida, Andrade, Liliana Lucci de Angelo, Fachini, Ana Maria Dias, Campbell, Leonardo Martins, Derchain, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848801/ https://www.ncbi.nlm.nih.gov/pubmed/24044637 http://dx.doi.org/10.1186/1471-2407-13-423

Ejemplares similares

Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers
por: Gomes, Tiago Augusto, et al.
Publicado: (2020)

Clinical Features and Management of Women with Borderline Ovarian Tumors in a Single Center in Brazil
por: Yoshida, Adriana, et al.
Publicado: (2019)

Strict Criteria for Selection of Laparoscopy for Women with Adnexal Mass
por: Barreta, Amilcar, et al.
Publicado: (2014)

Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocol
por: Campbell, Leonardo Martins, et al.
Publicado: (2013)

Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status
por: Sallum, Luis Felipe, et al.
Publicado: (2013)

Diagnostic Value of the Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Thrombocytosis in the Preoperative Investigation of Ovarian Masses
por: Yoshida, Adriana, et al.
Publicado: (2020)

Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses
por: Nunes Pereira, Patrick, et al.
Publicado: (2023)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses
por: Song, Liyun, et al.
Publicado: (2023)

WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis
por: Sallum, Luis Felipe, et al.
Publicado: (2018)

Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam
por: Huy, Nguyen Vu Quoc, et al.
Publicado: (2018)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
por: Feng, Li-yuan, et al.
Publicado: (2020)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer
por: Ferracini, Amanda Canato, et al.
Publicado: (2020)

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
por: Hamed, Elham O, et al.
Publicado: (2013)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

CAISMOV24, a new human low-grade serous ovarian carcinoma cell line
por: da Silva, Rodrigo Fernandes, et al.
Publicado: (2017)

CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages
por: Wang, Zhiheng, et al.
Publicado: (2019)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
por: Rong, Yan, et al.
Publicado: (2021)

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
por: Wan, Qiuhua, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
por: Dochez, Vincent, et al.
Publicado: (2019)

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
por: Kalapotharakos, Grigorios, et al.
Publicado: (2012)

Molecular Signatures of High-Grade Cervical Lesions
por: Porcari, Andreia M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_se901m1sa2vp6ajsd728mphk3g